Scarica l'app Stockscreener
276.45
2.29%
6.19
Dopo l'orario di chiusura:
281.97
5.52
+2.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KRYS Giù?
Forum
Previsione
Precedente Chiudi:
$270.26
Aprire:
$271.27
Volume 24 ore:
357.31K
Relative Volume:
1.29
Capitalizzazione di mercato:
$8.02B
Reddito:
$290.51M
Utile/perdita netta:
$89.16M
Rapporto P/E:
92.46
EPS:
2.99
Flusso di cassa netto:
$119.18M
1 W Prestazione:
+1.36%
1M Prestazione:
-5.30%
6M Prestazione:
+85.11%
1 anno Prestazione:
+77.50%
Intervallo 1D:
$271.27
$280.54
Intervallo di 1 settimana:
$264.85
$280.54
Portata 52W:
$122.80
$295.98
Krystal Biotech Inc Stock (KRYS) Company Profile
Nome
Krystal Biotech Inc
Settore
Industria
Telefono
(412) 586-5830
Indirizzo
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
276.45 | 7.84B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-05 | Iniziato | Jefferies | Buy |
| 2024-08-06 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Iniziato | Citigroup | Buy |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2023-02-28 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-18 | Iniziato | BofA Securities | Buy |
| 2021-07-20 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-06-04 | Iniziato | Evercore ISI | Outperform |
| 2019-09-24 | Iniziato | Goldman | Neutral |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-24 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-30 | Iniziato | Guggenheim | Buy |
| 2018-09-11 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Krystal Biotech Inc Borsa (KRYS) Ultime notizie
Soleus Adds a Significant Number of Celcuity Shares - The Motley Fool
Can Krystal Biotech Inc. sustain earnings growthJuly 2025 Final Week & Reliable Entry Point Trade Alerts - mfd.ru
Krystal Biotech: Flawless Vyjuvek Launch - AlphaStreet News
3 Growth Companies Insiders Are Betting On - simplywall.st
Krystal Biotech (NASDAQ:KRYS) CAO Sells $3,401,750.00 in Stock - MarketBeat
What are Krystal Biotech Inc.’s recent SEC filings showing2025 Top Decliners & Weekly High Return Opportunities - mfd.ru
Alps Advisors Inc. Decreases Stock Holdings in Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech (KRYS) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Krystal Biotech RMAT Win For KB707 And What It Means For Valuation - Sahm
Krystal Biotech wins FDA RMAT status for lung cancer therapy - MSN
Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update (NASDAQ:KRYS) - Seeking Alpha
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 - The Manila Times
FDA grants RMAT designation to Krystal Biotech’s lung cancer therapy By Investing.com - Investing.com South Africa
Krystal Biotech (KRYS) Gains FDA RMAT Status for Innovative Lung Cancer Therapy - GuruFocus
Krystal Biotech Receives FDA RMAT Designation for KB707 - Intellectia AI
Krystal Biotech wins FDA RMAT status for cancer drug (KRYS) - Seeking Alpha
Krystal Biotech Says US FDA Grants Regenerative Medicine Advanced Therapy Designation to Lung Cancer Treatment - marketscreener.com
FDA grants RMAT designation to Krystal Biotech’s lung cancer therapy - Investing.com
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of ... - Caledonian Record
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer - The Manila Times
FDA backs KB707 lung cancer immunotherapy with RMAT designation - Stock Titan
Krystal Biotech (NASDAQ:KRYS) Stock Rating Lowered by Zacks Research - MarketBeat
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? - MSN
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Federated Hermes Inc. Cuts Holdings in Krystal Biotech, Inc. $KRYS - MarketBeat
Vyjuvek Growth Powers Krystal Biotech’s (KRYS) Huge Upward Analyst Target Price Revision - Insider Monkey
Krystal Biotech (BIT:1KRYS) Price Target Increased by 11.47% to 252.42 - Nasdaq
Assessing Krystal Biotech (KRYS) Valuation After Analyst Optimism On Vyjuvek Expansion And Ophthalmic Pipeline - Sahm
Goldman Sachs Raises Price Target for Krystal Biotech (KRYS) | K - GuruFocus
Atle Fund Management AB Acquires 22,033 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech stock price target raised to $327 by Goldman Sachs - Investing.com Canada
Earnings Miss: Is Krystal Biotech Inc. impacted by rising ratesJuly 2025 Short Interest & Safe Entry Point Alerts - mfd.ru
US High Growth Tech Stocks To Watch For Potential Gains - simplywall.st
Krystal Biotech, Inc. $KRYS Shares Acquired by EFG Asset Management North America Corp. - MarketBeat
Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable - sharewise.com
Clear Street raises Krystal Biotech stock price target on KB801 potential - Investing.com Canada
Are you looking for a top momentum pick? Why Krystal Biotech, Inc. (KRYS) is a great choice - MSN
Assessing Krystal Biotech (KRYS) Valuation As Analyst Upgrades And Earnings Optimism Gain Traction - Sahm
Are You Looking for a Top Momentum Pick? Why Krystal Biotech, Inc. (KRYS) is a Great Choice - Yahoo Finance
Krystal Biotech, Inc. $KRYS Shares Sold by Maryland State Retirement & Pension System - MarketBeat
SG Americas Securities LLC Cuts Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Bank of America Increases Krystal Biotech (NASDAQ:KRYS) Price Target to $318.00 - MarketBeat
KRYS Sees New Price Target as B of A Securities Raises Outlook | - GuruFocus
Nasdaq Moves: Is Caribou Biosciences Inc. backed by strong institutional buyingSell Signal & Low Drawdown Investment Strategies - baoquankhu1.vn
Rate Cut: What drives Krystal Biotech Incs stock price2025 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
What does Wall Street think about Krystal Biotech (KRYS)? - MSN
Krystal Biotech, Inc. (KRYS) Stock Analysis: Evaluating the Healthcare Innovator’s Growth Potential - DirectorsTalk Interviews
What Does Wall Street Think About Krystal Biotech (KRYS)? - Finviz
Krystal Biotech (KRYS) Is Up 9.0% After Positive Interim Data From Inhaled CF Gene Therapy Study - Sahm
Krystal Biotech gets expanded FDA approval for Vyjuvek - MSN
Krystal Biotech Inc Azioni (KRYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Krystal Biotech Inc Azioni (KRYS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ROMANO KATHRYN | Chief Accounting Officer |
Feb 09 '26 |
Sale |
272.14 |
12,500 |
3,401,705 |
19,318 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):